Tower Research Capital LLC TRC Has $870,000 Position in Insulet Co. (NASDAQ:PODD)

Tower Research Capital LLC TRC grew its stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 65.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,332 shares of the medical instruments supplier's stock after purchasing an additional 1,323 shares during the quarter. Tower Research Capital LLC TRC's holdings in Insulet were worth $870,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of PODD. Norges Bank acquired a new stake in Insulet in the fourth quarter valued at $248,806,000. Raymond James Financial Inc. acquired a new stake in Insulet during the fourth quarter worth about $69,433,000. Alecta Tjanstepension Omsesidigt bought a new stake in shares of Insulet in the 4th quarter worth approximately $53,184,000. Artisan Partners Limited Partnership lifted its stake in Insulet by 24.1% in the fourth quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier's stock valued at $201,073,000 after buying an additional 149,524 shares during the last quarter. Finally, Marshall Wace LLP lifted its position in Insulet by 29.6% in the 4th quarter. Marshall Wace LLP now owns 486,516 shares of the medical instruments supplier's stock valued at $127,015,000 after purchasing an additional 111,119 shares during the last quarter.

Insulet Stock Performance

Insulet stock traded down $8.25 during trading hours on Tuesday, reaching $251.27. 1,152,259 shares of the company were exchanged, compared to its average volume of 715,741. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $289.46. The firm has a market cap of $17.65 billion, a price-to-earnings ratio of 43.40, a PEG ratio of 3.62 and a beta of 1.30. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The stock has a 50-day moving average of $259.72 and a 200 day moving average of $262.09.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The firm had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. As a group, research analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current year.

Insiders Place Their Bets

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the sale, the director now directly owns 3,231 shares of the company's stock, valued at $888,525. This represents a 36.10 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.47% of the company's stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. TD Cowen boosted their price target on Insulet from $264.00 to $324.00 and gave the stock a "buy" rating in a research report on Friday, January 3rd. Wells Fargo & Company set a $322.00 price objective on Insulet in a report on Monday. Royal Bank of Canada initiated coverage on Insulet in a report on Thursday, March 6th. They set an "outperform" rating and a $340.00 target price on the stock. Citigroup raised their price objective on shares of Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Finally, Raymond James reiterated an "outperform" rating and issued a $328.00 target price (up from $294.00) on shares of Insulet in a report on Friday, February 21st. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $292.06.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.